Neurogastrx

7EmployeesUS Form 5500 (plan participants) · Dec 2024

Facts

as of Nov 17, 2026

Neurogastrx, Inc.. Thank you for visiting the website for Neurogastrx, Inc. ("Company"), a privately held, late clinical-stage biopharmaceutical company formerly headquartered in Woburn, MA.

Legal name
Neurogastrx, Inc.
Headquarters
Woburn, United States
Founded
2017
Employees
7US Form 5500 (plan participants) · Dec 2024
Register numbers
NAME neurogastrx inc
Official records
SEC CIK 1870700
Website
neurogastrx.com

These are the key facts about Neurogastrx on Alion as of Nov 17, 2026. Neurogastrx is headquartered in Woburn, United States. It was founded in 2017. It has raised $80M in 2 funding rounds. The latest round is Venture - Series Unknown of $60M, announced in 2021.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Neurogastrx, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
SiteTypeOpen rolesHires most forEngineering
Woburn United StatesHeadquarters0
Source: office addresses in postings and company registers

Financials

Funding rounds, investors and revenue on record.

$80MTotal raised
Venture - Series UnknownLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
2021$80M2 records
Largest rounds and grants
Sources: funding announcements, grant and company registers

Milestones

Jun 25, 2021
Jun 18, 2021
2017
Founded
Each milestone is dated by its source: registers, filings, the press

Newsroom

Nov 7, 20252025
News · PRNewswire
PRN_FinancialWrapper
Oct 7, 20252025
News · markets.businessinsider.com
Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing A...
Sources: the outlets named on each headline, each story once